A new drug anifrolumab (IgG1κ monoclonal antibody to type I interferon receptor), at a dose of 300 mg IV every 4 weeks, may be added to standard therapy for the management of moderate to severe systemic lupus erythematosus, particularly in those with severe skin disease.